NEW YORK — As biotech speeds through a make-or-break September, a gaggle of banking conferences brought investors here this week, in hopes of separating the lucrative ideas from the lost causes.

We came, too, stalking the conference hallways (and open bars) in markedly less expensive clothing to take the pulse of biotech financiers in the middle of a hugely important time for the sector. Here, some scattered observations on biotech’s hottest topics:

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy